systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-81Research ArticleСТАТЬИARTICLESПрименение ингибиторов ангиотензинпревращающего фермента в лечении артериальной гипертонииГалявичА. С.noemail@neicon.ruКазанский государственный медицинский университетRussian Federation200623122022424649Copyright © Галявич А.С., 20222022Галявич А.С.Галявич А.С.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/81

На первом месте по числу назначений антигипертензивных средств находятся ингибиторы ангиотензинпревращающего фермента (ИАПФ) - 70,7%. Согласно химической классификации ИАПФ делятся на 3 группы в зависимости от наличия в молекуле ИАПФ окончания для присоединения к цинксодержащему рецептору мембраны клетки: 1-я группа содержит сульфгидрильную группу, 2-я группа - карбоксильную группу, 3-я группа - фосфорильную (фосфинильную) группу. У ИАПФ имеются многочисленные положительные эффекты, дающие им право занимать лидирующие позиции среди назначаемых антигипертензивных средств. ИАПФ являются препаратами первого выбора при наличии у больных АГ сопутствующей ХСН, а также после перенесенного инфаркта миокарда. ИАПФ показаны пациентам с АГ с сопутствующей ИБС, так как оказывают положительные эффекты на атеросклеротический процесс и состояние фибринолитической системы.

артериальная гипертонияантигипертензивные средстваингибиторы ангиотензинпревращающего ферментаReferencesШальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Рос. кардиол. журн. 2006; 4: 45-50.Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Рос. кардиол. журн. 2006; 4: 45-50.Ferreira S.H. A bradikinin - potentiating factor (BPF) present in the venom of Bothrops jararaca. Br J Pharmacol Chemother 1965; 24: 163-9.Ferreira S.H. A bradikinin - potentiating factor (BPF) present in the venom of Bothrops jararaca. Br J Pharmacol Chemother 1965; 24: 163-9.Yang H.Y, Erdos E.G, Levin E. A dipeptidyl carboxypeptidase that converts angiotensin-1 and inactivates bradykinin. Biochim Biophis Acta 1970; 214: 374-6.Yang H.Y, Erdos E.G, Levin E. A dipeptidyl carboxypeptidase that converts angiotensin-1 and inactivates bradykinin. Biochim Biophis Acta 1970; 214: 374-6.Cushman D.W, Ondetti M.A. Personal and historical perspectives: History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hyperetension 1991; 17: 589-92.Cushman D.W, Ondetti M.A. Personal and historical perspectives: History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hyperetension 1991; 17: 589-92.Patchett A.A, Harris E, Tristram E.W et al. A new class of angiotensin - converting enzyme inhibitors. Nature 1980; 288: 280-3.Patchett A.A, Harris E, Tristram E.W et al. A new class of angiotensin - converting enzyme inhibitors. Nature 1980; 288: 280-3.Opie L.H. Angiotensin converting enzyme inhibitors. Authors Publishing House, New York, 1992.Opie L.H. Angiotensin converting enzyme inhibitors. Authors Publishing House, New York, 1992.Johnston C.I. Angiotensin - converting enzyme inhibitors. In: Robertson J.I, Nicholson M.G. (ed.) The renin - angiotensin system. London, New York: Gower Medical Publishing 1993; 87.1-87.15.Johnston C.I. Angiotensin - converting enzyme inhibitors. In: Robertson J.I, Nicholson M.G. (ed.) The renin - angiotensin system. London, New York: Gower Medical Publishing 1993; 87.1-87.15.Murdoch D, Tavish D. Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension. Drugs 1992; 43: 123-40.Murdoch D, Tavish D. Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension. Drugs 1992; 43: 123-40.Wagstaff A.J, Davis R, Mc Tavish D. Fosinopril: a reapprasal of its pharmacological efficacy in essential hypertension. Drugs 1996; 51: 777-91.Wagstaff A.J, Davis R, Mc Tavish D. Fosinopril: a reapprasal of its pharmacological efficacy in essential hypertension. Drugs 1996; 51: 777-91.Lund-Johansen P, Omvik P. Long - term haemodynamic effects of enalapril (alone and in combination with hydrochlorothiazide) at rest and during exercise in essential hypertension. J Hypertens 1984; 2: S49-50.Lund-Johansen P, Omvik P. Long - term haemodynamic effects of enalapril (alone and in combination with hydrochlorothiazide) at rest and during exercise in essential hypertension. J Hypertens 1984; 2: S49-50.Ibsen H, Egan B, Osterzeil K, Vander A, Julius S. Reflex - hemodynamic adjustments and baroreflex sensitivity during converting enzyme inhibition with MK-421 in normal humans. Hypertension 1983; 5 (suppl. I): I-184-I-9.Ibsen H, Egan B, Osterzeil K, Vander A, Julius S. Reflex - hemodynamic adjustments and baroreflex sensitivity during converting enzyme inhibition with MK-421 in normal humans. Hypertension 1983; 5 (suppl. I): I-184-I-9.Dunn G.F, Oigman W, Ventura H.O et al. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol 1984; 53: 105-8.Dunn G.F, Oigman W, Ventura H.O et al. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol 1984; 53: 105-8.Simon A.C, Levenson J.A, Bouthier J et al. Effects of acute and chronic angiotensin enzyme inhibition on large arteries in human hypertension. J Cardiovasc Pharmacol 1985; 7: S45-51.Simon A.C, Levenson J.A, Bouthier J et al. Effects of acute and chronic angiotensin enzyme inhibition on large arteries in human hypertension. J Cardiovasc Pharmacol 1985; 7: S45-51.Cody R.J, Tarazi R.C, Bravo E.L, Fouad F.M. Haemodynamics of orallyactive converting enzyme inhibitor (SQ 14225) in hypertensive patients. Clin Sci Mol Med 1978; 55: 453-9.Cody R.J, Tarazi R.C, Bravo E.L, Fouad F.M. Haemodynamics of orallyactive converting enzyme inhibitor (SQ 14225) in hypertensive patients. Clin Sci Mol Med 1978; 55: 453-9.Fouad F.M, Tarazi R.C, Bravo E.L. Cardiac and haemodynamic effects of enalapril. J Hypertens 1983; 1 (suppl. 1): 135-42.Fouad F.M, Tarazi R.C, Bravo E.L. Cardiac and haemodynamic effects of enalapril. J Hypertens 1983; 1 (suppl. 1): 135-42.Fagard R, Amery A, Reybrouck T et al. Acute and chronic systemic and hemodynamic effects of angiotensin converting enzyme inhibition with captopril in hypertensive patients. Am J Cardiol 1980; 46: 295-300.Fagard R, Amery A, Reybrouck T et al. Acute and chronic systemic and hemodynamic effects of angiotensin converting enzyme inhibition with captopril in hypertensive patients. Am J Cardiol 1980; 46: 295-300.Tarazi R.C, Bravo E.L, Fouad F.M et al. Hemodynamic and volume changes associated with captopril. Hypertension 1980; 2: 576-85.Tarazi R.C, Bravo E.L, Fouad F.M et al. Hemodynamic and volume changes associated with captopril. Hypertension 1980; 2: 576-85.Muiesan G, Alicandri C.L, Agabiti-Rosei E et al. Angiotensin - converting enzyme inhibition, catecholamines and hemodynamics in essential hypertension. Am J Cardiol 1982; 49: 1420-4.Muiesan G, Alicandri C.L, Agabiti-Rosei E et al. Angiotensin - converting enzyme inhibition, catecholamines and hemodynamics in essential hypertension. Am J Cardiol 1982; 49: 1420-4.Horning B, Landmesser U, Kohler C et al. Comparative effects of ace inhibition and angiotensin II type receptor antagonism on bioavailability of nitric oxide in patients with coronary heart disease: role of superoxide dismutase. Circulation 2001; 103: 799-805.Horning B, Landmesser U, Kohler C et al. Comparative effects of ace inhibition and angiotensin II type receptor antagonism on bioavailability of nitric oxide in patients with coronary heart disease: role of superoxide dismutase. Circulation 2001; 103: 799-805.Horning B, Arakawa N, Drexler H. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. Eur Heart J 1998; 19 (Suppl. G): G48-53.Horning B, Arakawa N, Drexler H. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. Eur Heart J 1998; 19 (Suppl. G): G48-53.Brunner H.R, Gavras H, Waeber B et al. Oral angiotensin - converting enzyme inhibitor in long - term treatment of hypertensive patients. Ann Intern Med 1979; 90: 19-23.Brunner H.R, Gavras H, Waeber B et al. Oral angiotensin - converting enzyme inhibitor in long - term treatment of hypertensive patients. Ann Intern Med 1979; 90: 19-23.Gavras H, Brunner H.R, Turini G.A et al. Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ 14225 in man. N Engl J Med 1978; 298: 991-5.Gavras H, Brunner H.R, Turini G.A et al. Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ 14225 in man. N Engl J Med 1978; 298: 991-5.Vander A.J, Geelhoed G.W. Inhibition of renin secretion by angiotensin II. Proc Soc Exp Biol Med 1965; 120: 399-403.Vander A.J, Geelhoed G.W. Inhibition of renin secretion by angiotensin II. Proc Soc Exp Biol Med 1965; 120: 399-403.Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta - analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta - analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.Brilla C.G, Janicki J.S, Weber K.T. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991; 83: 1771-9.Brilla C.G, Janicki J.S, Weber K.T. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991; 83: 1771-9.Weber J.R. Left ventricular hypertrophy: its prevalence, etiology and significance. Clin Cardiol 1991; 14 (Suppl. III): 13-7.Weber J.R. Left ventricular hypertrophy: its prevalence, etiology and significance. Clin Cardiol 1991; 14 (Suppl. III): 13-7.Peng H, Carretero O, Vuljaj N et al. Angiotensin-Converting Enzyme Inhibitors: A New Mechanism of Action. Circulation 2005; 112 (16): 2436-45.Peng H, Carretero O, Vuljaj N et al. Angiotensin-Converting Enzyme Inhibitors: A New Mechanism of Action. Circulation 2005; 112 (16): 2436-45.Schlueter W.A, Battle D.C. Renal effects of antihypertensve drugs. Drugs 1989; 37: 900-25.Schlueter W.A, Battle D.C. Renal effects of antihypertensve drugs. Drugs 1989; 37: 900-25.Hall J.E. Intrarenal actions of converting enzyme inhibitors. Am J Hypertns 1989; 2: 875-84.Hall J.E. Intrarenal actions of converting enzyme inhibitors. Am J Hypertns 1989; 2: 875-84.Nishijama K, Igari T, Nanda S, Ishii M. Long - term effects of delapril on renal function annd urinary excretion of kallikrein, prostaglandin E2, and thromboxan B2 in hypertensive patients. Am J Hypertens 1991; 4: 52S-3S.Nishijama K, Igari T, Nanda S, Ishii M. Long - term effects of delapril on renal function annd urinary excretion of kallikrein, prostaglandin E2, and thromboxan B2 in hypertensive patients. Am J Hypertens 1991; 4: 52S-3S.Brichard S, Lambert A.E. Perindopril safety and tolerance in at risk patients. Drugs 1990; 39 (Suppl. 1): 64-70.Brichard S, Lambert A.E. Perindopril safety and tolerance in at risk patients. Drugs 1990; 39 (Suppl. 1): 64-70.Vaughan D.E, Lazos S.A, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 1995; 95: 995-1001.Vaughan D.E, Lazos S.A, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 1995; 95: 995-1001.Ridker P.M, Gaboury C.L, Conlin P.R et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Circulation 1993; 87: 1969-73.Ridker P.M, Gaboury C.L, Conlin P.R et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Circulation 1993; 87: 1969-73.Emeis J.J, Tranquille N. On the role of bradykinin in secretion from vascular endothelial cells. Agents Actions 1992; 38: 285-91.Emeis J.J, Tranquille N. On the role of bradykinin in secretion from vascular endothelial cells. Agents Actions 1992; 38: 285-91.Brown N.J, Nadeau J, Vaughan D.E. Selective stimulation of tissue - type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 1997; 77: 522-5.Brown N.J, Nadeau J, Vaughan D.E. Selective stimulation of tissue - type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 1997; 77: 522-5.Pitt B. Potential role of angiotensin converting enzyme inhibitors in the treatment of atherosclerosis. Eur Heart J 1995; 16: 49-54.Pitt B. Potential role of angiotensin converting enzyme inhibitors in the treatment of atherosclerosis. Eur Heart J 1995; 16: 49-54.Schoelkens B.A, Landgraf W. ACE inhibition and atherosclerosis. Can J Physiol Pharm 2002; 80: 354-9.Schoelkens B.A, Landgraf W. ACE inhibition and atherosclerosis. Can J Physiol Pharm 2002; 80: 354-9.Dagenais G.R, Pogue J, Fox K et al. Angiotensin - converting - enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368 (9535): 581-8.Dagenais G.R, Pogue J, Fox K et al. Angiotensin - converting - enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368 (9535): 581-8.Zanchetti A, Crepaldi G, Bond G et al. Different Effects of Antihypertensive Regimens Based on Fosinopril or Hydrochlorothiazide With or Without Lipid Lowering by Pravastatin on Progreesion of Asymptomatic Carotid Atherosclerosis. Stroke 2004; 35:Zanchetti A, Crepaldi G, Bond G et al. Different Effects of Antihypertensive Regimens Based on Fosinopril or Hydrochlorothiazide With or Without Lipid Lowering by Pravastatin on Progreesion of Asymptomatic Carotid Atherosclerosis. Stroke 2004; 35:Zhuo J, Moeller I, Jenkins T et al. Mapping tissue angiotensin - converting enzyme and angiotensin AT1, AT2 and AT4 receptors. J Hypertens 1998; 16: 2027-37.Zhuo J, Moeller I, Jenkins T et al. Mapping tissue angiotensin - converting enzyme and angiotensin AT1, AT2 and AT4 receptors. J Hypertens 1998; 16: 2027-37.Opie L.H. Angiotensin Converting Enzyme Inhibitors. The Advance Continues. Third Edition. Authors Publishing House. New York. 1999.Opie L.H. Angiotensin Converting Enzyme Inhibitors. The Advance Continues. Third Edition. Authors Publishing House. New York. 1999.The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin - converting - enzyme inhibitor, ramipril, on cardiovascular events in high - risk patients. N Engl J Med 2000; 342: 145-53.The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin - converting - enzyme inhibitor, ramipril, on cardiovascular events in high - risk patients. N Engl J Med 2000; 342: 145-53.Bosch J, Yusuf S, Pogue J et al. HOPE Investigators. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324: 699-702.Bosch J, Yusuf S, Pogue J et al. HOPE Investigators. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324: 699-702.PROGRESS Collaborative Group. Randomised trial of a perindopril - based blood - pressure - lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.PROGRESS Collaborative Group. Randomised trial of a perindopril - based blood - pressure - lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.Hansson L, Lindholm L, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial on Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6.Hansson L, Lindholm L, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial on Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6.Hansson L, Lindholm L, Niskanen L et al. Effect of angiotensin - converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999; 353: 611-6.Hansson L, Lindholm L, Niskanen L et al. Effect of angiotensin - converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999; 353: 611-6.Wing L.M, Reid C.M, Ryan P et al. A comparison of outcomes with angiotensin - converting enzyme inhibitors and diuretics for hypertension in the erderly. N Engl J Med 2003; 348: 583-92.Wing L.M, Reid C.M, Ryan P et al. A comparison of outcomes with angiotensin - converting enzyme inhibitors and diuretics for hypertension in the erderly. N Engl J Med 2003; 348: 583-92.Рекомендации ВНОК "Профилактика, диагностика и лечение артериальной гипертензии", 2-й пересмотр. М., 2004.Рекомендации ВНОК "Профилактика, диагностика и лечение артериальной гипертензии", 2-й пересмотр. М., 2004.Kang P.M, Landau A.J, Eberhardt R.T, Frishman W.H. Angiotensin II receptor antagonists: a new approach to blockade of the renin - angiotensin system Am Heart J 1994; 127: 1388-401.Kang P.M, Landau A.J, Eberhardt R.T, Frishman W.H. Angiotensin II receptor antagonists: a new approach to blockade of the renin - angiotensin system Am Heart J 1994; 127: 1388-401.Ferner R.E, Simpson J.M, Rawlins M.D. Effects of intradermal bradykininn after inhibition of angiotensin converting enzyme. Br Med J 1987; 294: 1119-20.Ferner R.E, Simpson J.M, Rawlins M.D. Effects of intradermal bradykininn after inhibition of angiotensin converting enzyme. Br Med J 1987; 294: 1119-20.

The authors declare that there are no conflicts of interest present.